PRODUCT FILTER
Categories
Type
Type

Partamol Codeine eff.
Rx

Paracetamol and codeine phosphate tablets combine the analgesic effects of a centrally acting analgesic, codeine, with a peripherally acting analgesic, paracetamol.

Pack size Box of 4 strips x 4 tablets. Box of 1 tube, 2 tubes x 10 tablets
Shelf-life 36 months
Composition Paracetamol, Codeine phosphate
Dosage forms and strengths Effervescent tablet:
Paracetamol 500 mg, Codeine phosphate 30 mg
Product code :

PRESCRIBING INFORMATION

Indications:

For the relief of mild to moderately severe pain.

Dosage:

  • Partamol-Codeine should be used at the lowest effective dose for the shortest period of time. Dosage should be adjusted according to severity of pain and response.
  • Adults: ½ -2 tablets, maximum of 8 tablets in 24 hours. Doses may be repeated up to every 4 hours.

Usage:

Partamol-Codeine effervescent tablet is administered orally. Dissolve tablet in a glass of water.

Known hypersensitivity to any of the active substances or excipients.

Patients with impaired kidney or liver function, alcohol dependence,

Patients with deficiency of glucose – 6 – phosphate dehydrogenase.

All paediatric patients (≤ 18 years of age) who undergo tonsillectomy and/or adenoidectomy.

Lightheadedness, dizziness, sedation, shortness of breath, nausea and vomiting; allergic reactions, euphoria, dysphoria, constipation, abdominal pain and pruritus; at higher doses, respiratory depression can occur.

Using this drug may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

The respiratory depressant effects and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure.

This drug should be given with caution to certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison’s disease, and prostatic hypertrophy or urethral stricture.

Codeine can produce drug dependence of the morphine type and, therefore, has the potential for being abused.

Because of a risk of respiratory depression, codeine is only indicated in patients older than 12 years of age for the treatment of acute moderate pain that cannot be relieved by other analgesics such as paracetamol or ibuprofen (alone). Codeine is not recommended for use in children with breathing problems and children below 12 years of age.

Caution is recommended when giving codeine to breastfeeding mothers. Infrequent paracetamol should remain the analgesic of choice in pregnancy. Paracetamol and codeine phosphate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Patients should refrain from driving, engaging in potentially hazardous activities or operating machinery.

The physicians need to warn the patients of the signs of serious skin reactions known as Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) or Lyell’s syndrome, acute generalized exanthematous pustulosis (AGEP).